FOLH1 and posterior cortical atrophy: Although the standard treatment for oligorecurrent hormone-sensitive prostate cancer (HSPC) usually consists of systemic combination treatment with androgen receptor-targeted agents (ARTA) and androgen deprivation therapy (ADT) [4–6], PSMA-radioguided surgery (RGS), which is still considered experimental, has been shown to be effective in removing PCa metastases and achieving consecutive PSA responses [7].